Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2017 Aug;24(4):285–291. doi: 10.1097/MED.0000000000000348

Figure 2.

Figure 2

Cumulative incidence of T1D development in subjects with single IAb in TrialNet Pathway to Prevention Study.

Panel A: Cumulative incidence of T1D development in subjects with single GADA positive by RBA, divided with ECL-GADA positive vs ECL-GADA negative (p= 0.0009).

Panel B: Cumulative incidence of T1D development in subjects with single IAA positive by RBA, divided with ECL-IAA positive vs ECL-IAA negative (p< 0.0001).